Prostate Cancer
Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.
October 23, 2023
Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: A Canadian bicentric study and comparison with 2010 data.
October 23, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
October 20, 2023
Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade.
October 20, 2023
Health-Related Quality of Life Assessment in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy: Real-World Experience in the READT Study.
October 20, 2023
Comparative analysis of robot-assisted and open approach for PSMA-radioguided surgery in recurrent prostate cancer.
October 19, 2023
Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer.
October 19, 2023
Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
October 18, 2023
Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer: Oncological Outcomes and Toxicity Profile.
October 18, 2023
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
October 18, 2023